Freya Biosciences Has $38m And A Plan To Change Women’s Lives
Executive Summary
Emerging Company Profile: Armed with a new tranche of funding, the Danish group is aiming to improve the lot of infertile couples by altering the microbiome of patients with dysbiosis.
You may also be interested in...
IPOs Fizzle Out In The Fourth Quarter
Just three biotech companies floated in the last three months of 2023, but there may be hope for a resurgence next year.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.